Display options
Cite
Martínez LE, Lensing S, Chang D, et al. Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. Clin Cancer Res. 2021;27(16):4642-4651doi: 10.1158/1078-0432.CCR-20-4167.
Martínez, L. E., Lensing, S., Chang, D., Magpantay, L. I., Mitsuyasu, R., Ambinder, R. F., Sparano, J. A., Martínez-Maza, O., & Epeldegui, M. (2021). Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(16), 4642-4651. https://doi.org/10.1158/1078-0432.CCR-20-4167
Martínez, Laura E, et al. "Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,16 (2021): 4642-4651. doi: https://doi.org/10.1158/1078-0432.CCR-20-4167
Martínez LE, Lensing S, Chang D, Magpantay LI, Mitsuyasu R, Ambinder RF, Sparano JA, Martínez-Maza O, Epeldegui M. Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. Clin Cancer Res. 2021 Aug 15;27(16):4642-4651. doi: 10.1158/1078-0432.CCR-20-4167. Epub 2021 Jun 15. PMID: 34131000; PMCID: PMC8364886.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 Aug 15;27(16):4642-4651. doi: 10.1158/1078-0432.CCR-20-4167. Epub 2021 Jun 15.

Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Laura E Martínez, Shelly Lensing, Di Chang, Larry I Magpantay, Ronald Mitsuyasu, Richard F Ambinder, Joseph A Sparano, Otoniel Martínez-Maza, Marta Epeldegui

Affiliations

  1. UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, California.
  2. Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, California.
  3. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  4. Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  5. Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
  6. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California.
  7. UCLA AIDS Institute and David Geffen School of Medicine, University of California, Los Angeles, California. [email protected].

PMID: 34131000 PMCID: PMC8364886 DOI: 10.1158/1078-0432.CCR-20-4167

Abstract

PURPOSE: AIDS-related non-Hodgkin lymphoma (ARL) is the most common cancer in HIV-infected individuals in the United States and other countries in which HIV-positive persons have access to effective combination antiretroviral therapy (cART). Our prior work showed that pretreatment/postdiagnosis plasma levels of some cytokines, such as IL6, IL10, and CXCL13, have the potential to serve as indicators of clinical response to treatment and survival in ARL. The aims of this study were to identify novel prognostic biomarkers for response to treatment and/or survival in persons with ARL, including biomarkers of microbial translocation and inflammation.

EXPERIMENTAL DESIGN: We quantified plasma levels of several biomarkers (sCD14, LBP, FABP2, EndoCab IgM, IL18, CCL2/MCP-1, sCD163, IP-10/CXCL10, TARC/CCL17, TNFα, BAFF/BLyS, sTNFRII, sCD44, and sIL2Rα/sCD25) by multiplexed immunometric assays (Luminex) or ELISA in plasma specimens obtained from ARL patients enrolled in the AMC-034 trial, which compared infusional combination chemotherapy (EPOCH: etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone) with concurrent or sequential rituximab. Plasma was collected prior to the initiation of therapy (

RESULTS: We found that several biomarkers decreased significantly after treatment, including TNFα, sCD25, LBP, and TARC (CCL17). Moreover, pretreatment plasma levels of BAFF, sCD14, sTNFRII, and CCL2/MCP-1 were univariately associated with overall survival, and pretreatment levels of BAFF, sTNFRII, and CCL2/MCP-1 were also associated with progression-free survival.

CONCLUSIONS: Our results suggest that patients with ARL who responded to therapy had lower pretreatment levels of inflammation and microbial translocation as compared with those who did not respond optimally.

©2021 American Association for Cancer Research.

References

  1. Ann Hematol. 2019 Feb;98(2):413-422 - PubMed
  2. For Immunopathol Dis Therap. 2015;6(1-2):79-90 - PubMed
  3. J Clin Oncol. 2005 Nov 20;23(33):8477-82 - PubMed
  4. J Infect Dis. 2014 Oct 1;210(7):1042-6 - PubMed
  5. Immunol Res. 2010 Dec;48(1-3):72-83 - PubMed
  6. AIDS. 2018 Apr 24;32(7):945-954 - PubMed
  7. Cancer. 1999 Dec 1;86(11):2391-7 - PubMed
  8. Clin Microbiol Rev. 2013 Jan;26(1):2-18 - PubMed
  9. AIDS. 2015 Feb 20;29(4):463-71 - PubMed
  10. Diabetologia. 2014 Feb;57(2):366-72 - PubMed
  11. AIDS. 2015 Jun 19;29(10):1263-5 - PubMed
  12. Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 - PubMed
  13. Blood. 2010 Apr 15;115(15):3008-16 - PubMed
  14. J Infect Dis. 2014 Oct 15;210(8):1248-59 - PubMed
  15. J Infect Dis. 2011 Mar 15;203(6):780-90 - PubMed
  16. Lupus. 2018 Jun;27(7):1100-1106 - PubMed
  17. AIDS. 2006 Aug 1;20(12):1645-54 - PubMed
  18. Cell Commun Signal. 2020 May 29;18(1):82 - PubMed
  19. J Clin Immunol. 1988 Nov;8(6):447-52 - PubMed
  20. J Clin Oncol. 1998 Nov;16(11):3601-6 - PubMed
  21. AIDS. 2014 Mar 27;28(6):881-90 - PubMed
  22. Haematologica. 1998 Jun;83(6):508-13 - PubMed
  23. AIDS. 2020 Aug 1;34(10):1467-1473 - PubMed
  24. Crit Rev Oncol Hematol. 2014 Aug;91(2):113-22 - PubMed
  25. Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):343-9 - PubMed
  26. Clin Cancer Res. 2016 Jan 15;22(2):328-36 - PubMed
  27. Sci Rep. 2018 Sep 24;8(1):14277 - PubMed
  28. Haematologica. 2014 Nov;99(11):1731-7 - PubMed
  29. Curr Opin HIV AIDS. 2017 Jan;12(1):6-11 - PubMed
  30. Curr Opin Oncol. 2006 Sep;18(5):444-8 - PubMed
  31. Nat Rev Microbiol. 2012 Sep;10(9):655-66 - PubMed
  32. AIDS. 2016 Jul 17;30(11):1795-806 - PubMed
  33. J Natl Cancer Inst. 2018 Jun 1;110(6):598-607 - PubMed
  34. Curr Opin HIV AIDS. 2016 Mar;11(2):182-90 - PubMed
  35. Blood. 1998 Sep 15;92(6):2084-92 - PubMed
  36. Haematologica. 2018 Oct;103(10):1679-1687 - PubMed
  37. Neurol Neuroimmunol Neuroinflamm. 2020 May 11;7(4): - PubMed
  38. Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):295-307 - PubMed
  39. AIDS Res Ther. 2016 Apr 11;13:19 - PubMed
  40. Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1303-14 - PubMed
  41. Blood. 2006 Dec 1;108(12):3786-91 - PubMed
  42. Int J Cancer. 2008 Jul 1;123(1):187-94 - PubMed
  43. Clin Cancer Res. 2011 May 15;17(10):3056-63 - PubMed
  44. Cancer. 2010 Dec 1;116(23):5507-16 - PubMed
  45. J Clin Oncol. 1996 Aug;14(8):2217-23 - PubMed
  46. PLoS One. 2010 Jul 06;5(7):e11448 - PubMed
  47. Curr Opin Oncol. 2002 Sep;14(5):528-32 - PubMed
  48. Am Rev Respir Dis. 1988 Apr;137(4):759-64 - PubMed
  49. Curr Opin HIV AIDS. 2017 Jan;12(1):39-46 - PubMed
  50. AIDS Res Treat. 2010;2010:164586 - PubMed
  51. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122-129 - PubMed
  52. N Engl J Med. 1993 Sep 30;329(14):987-94 - PubMed
  53. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2084-93 - PubMed

Publication Types

Grant support